PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11590226-15	2001	In contrast, if the cells were depleted of cholesterol by incubating them with lovastatin and cyclodextrin, the mature forms of SREBP-1 and SREBP-2 were increased, as were mRNA levels for the sterol-responsive genes.	Lovastatin	79-89	sterol regulatory element binding transcription factor 2	Homo sapiens	140-147	
26784701-9	2016	Interestingly, camphene increased the nuclear translocation of the mature form of SREBP-1 while mevinolin was found to increase the amount of the mature form of SREBP-2.	Lovastatin	96-105	sterol regulatory element binding transcription factor 2	Homo sapiens	161-168	
7862668-7	1995	Depletion of sterols by treatment with a bile acid-binding resin (colestipol) and a cholesterol synthesis inhibitor (mevinolin) led to a marked increase in the nuclear form of SREBP-2 and a reciprocal decline in the nuclear form of SREBP-1.	Lovastatin	117-126	sterol regulatory element binding transcription factor 2	Homo sapiens	176-183	
9356453-9	1997	Treatment with lovastatin and Colestipol, which increases hepatic demands for cholesterol, increased the amount of SREBP-2 mRNA as well as the precursor and nuclear forms of the protein.	Lovastatin	15-25	sterol regulatory element binding transcription factor 2	Homo sapiens	115-122	
30466075-11	2018	Moreover, lovastatin increased the expression of SREBP-2 and miR-33a, which were then downregulated by SREBP-2 silencing.	Lovastatin	10-20	sterol regulatory element binding transcription factor 2	Homo sapiens	49-56	
30466075-11	2018	Moreover, lovastatin increased the expression of SREBP-2 and miR-33a, which were then downregulated by SREBP-2 silencing.	Lovastatin	10-20	sterol regulatory element binding transcription factor 2	Homo sapiens	103-110	
30466075-14	2018	SREBP-2 silencing or miR-33a inhibitor upregulated CYR61 expression and reversed the effects of lovastatin on cell invasion and EMT-related proteins.	Lovastatin	96-106	sterol regulatory element binding transcription factor 2	Homo sapiens	0-7	
30466075-15	2018	CONCLUSION: Our findings suggest lovastatin suppresses osteosarcoma cell invasion through the SREBP-2/miR-33a/CYR61 pathway.	Lovastatin	33-43	sterol regulatory element binding transcription factor 2	Homo sapiens	94-101	
17142457-4	2007	Immunoblots indicate that lovastatin-treated human hepatocytes display increased proteolytic processing of SREBP-2.	Lovastatin	26-36	sterol regulatory element binding transcription factor 2	Homo sapiens	107-114	
20459026-9	2010	Cellular cholesterol was decreased and the expression of SREBP-2 and LDLR were up-regulated by Lovastatin.	Lovastatin	95-105	sterol regulatory element binding transcription factor 2	Homo sapiens	57-64	
26096465-9	2015	However, lovastatin induced a remarkable increase in the mature form of the sterol regulatory element-binding protein-2 (SREBP-2) as well as its target gene HMGCR, in both neuronal cells and in the brain.	Lovastatin	9-19	sterol regulatory element binding transcription factor 2	Homo sapiens	76-119	
26096465-9	2015	However, lovastatin induced a remarkable increase in the mature form of the sterol regulatory element-binding protein-2 (SREBP-2) as well as its target gene HMGCR, in both neuronal cells and in the brain.	Lovastatin	9-19	sterol regulatory element binding transcription factor 2	Homo sapiens	121-128	
17142457-5	2007	In HepG2 cells, co-administration of a potent suppressor of SREBP-2 activation, 25-hydroxycholesterol, inhibits CYP4F2 mRNA induction by lovastatin.	Lovastatin	137-147	sterol regulatory element binding transcription factor 2	Homo sapiens	60-67